|Articles|October 19, 2021
Daily Medication Pearl: Ibrexafungerp (BREXAFEMME) for Vulvovaginal Candidiasis
Author(s)Saro Arakelians, PharmD
Ibrexafungerp is a triterpenoid antifungal drug for adult and post-menarchal pediatric females with vulvovaginal candidiasis.
Advertisement
Medication Pearl of the Day: Ibrexafungerp (BREXAFEMME)
Indication: Ibrexafungerp is a triterpenoid antifungal indicated for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis.
Insight:
- Dosing: The recommended dosage of ibrexafungerp in adult and post-menarchal pediatric females is 300 mg (2 tablets of 150 mg) twice a day for 1 day, for a total treatment dosage of 600 mg.
- Dosage form: Tablets 150 mg.
- Adverse events (AEs): The most frequent AEs associated with this drug are diarrhea, nausea, abdominal pain, dizziness, and vomiting.
- Mechanism of action: Ibrexafungerp is a triterpenoid antifungal drug.
- Manufacturer: Scynexis
Sources:
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
White House Expands TrumpRx, Adding Over 600 Generic Medications
2
FDA Approves Immgolis and Immgolis Intri as First Biosimilars to Golimumab Reference Products for RA and UC
3
FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor for Hypertension
4
Insulin Deprescribing Utilizing Continuous Glucose Monitoring With Low-Dose Tirzepatide
5